Showing 1672 results
-
Press release /PEARL 1 and PEARL 2, the largest pivotal trials to date in chronic spontaneous urticaria (CSU), will enroll more than 2,000 CSU patients[1],[2] Ligelizumab (QGE031), a monoclonal antibody…
-
Press release /Phase II study efficacy data showed overall response rate of 72.0% and 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small…
-
Press release /Up to 80% of relapsing remitting MS (RRMS) patients transition to secondary progressive MS (SPMS)[1], a stage of the disease leading to continuous functional decline, which is often undiagnosed or…
-
Press release /
Novartis sickle cell medicine Adakveo® approved in Europe to prevent recurrent vaso-occlusive crises
Adakveo is the first targeted sickle cell disease therapy for prevention of recurrent vaso-occlusive crises (VOCs) available for use in EuropeClinical data showed that use of Adakveo led to a… -
Press release /Novartis leprosy medicine donation program with WHO extended to 2025 Program has already treated over 7 million patients since 2000 New evidence from contact tracing and preventive treatment…
-
Ad hoc release /Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (IT) formulation in older patients with SMA to further support registration Basel,…
-
Press release /Ultibro® Breezhaler® met primary endpoint and demonstrated superiority to Seretide® in reducing COPD exacerbations during 52 weeks of treatment First large-scale study to confirm Ultibro…
-
Ad hoc release /SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase…
-
Press release /Xolair® (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU)[1], is the only therapy recommended by the guideline for patients unresponsive to…
-
Press release /74% of patients in MEASURE 2 achieved clinically significant and sustained improvement in symptoms of ankylosing spondylitis (AS) with secukinumab 150 mg after one year of treatment[1] AS is…